title: [Clinical trial on safety of inactivated split influenza virus vaccine, Anflu in 2007-2008].
abstract: OBJECTIVE
  To review the safety of the inactivated split influenza vaccine, Anflu in a large scale population.
  
  
  METHODS
  Selecting 14 districts national wide to inject the inactivated split influenza vaccines according schedules among infants, children, youths, adults and elder respectively. All volunteers were observed for AEFI after 7 days vaccinated.
  
  
  RESULTS
  A total of 2794 volunteers aged 6 months to 90 years were enrolled in trials. The overall rate of adverse events was 6.6%.most adverse was mild reaction. Severe, infrequent or new adverse events were not reported. The rate of local reactions was 2.1%. The rate of local pain was 1.7%. The rate of systematic adverse events was 5.0%, fever took up 3.8%.
  
  
  CONCLUSIONS
  The inactivated split influenza vaccine, Anflu was safe.
authors.affiliation: Sinovac Biotech Co., Ltd, Beijing 100085, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Yan-Wei
authors.initials: YW
authors.lastname: Zhao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines; D015164:Vaccines, Inactivated